CorMedix price target lowered to $13 from $14 at RBC Capital
RBC Capital lowered the firm's price target on CorMedix to $13 from $14 and keeps an Outperform rating on the shares as part of a broader research note previewing Q2 earnings in Biotech. The biotech sector has picked up considerable momentum, with a near-unprecedented two-week move in June relative to the S&P - driven